According to preliminary study results, 15 existing drugs approved by the U.S. Food and Drug Administration (FDA) have the potential to slow or reverse brain damage in those with Alzheimer’s disease (AD) and another 14 for Parkinson Disease, Lou Gehrig's disease (amyotrophic lateral sclerosis, or ALS) or stroke. These 15 existing drugs had been FDA-approved for other purposes, which would expedite clinical trials that would otherwise be put on hold due to needed approval.

The list of potential drugs was determined by referencing a list of proteins present in the brain, cerebrospinal fluid, and blood plasma . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

The News

Daily coverage of the developments shaping health and human services. From policy shifts to program innovations, reports on trends-shaping mental health, addiction treatment, child and family services, autism and I/DD, disability support and long-term care, social services, corrections, juvenile justice, chronic disease management, health care systems, and more-helping leaders make timely, informed decisions.

Filter Options

  • By Market
  • By Topic
  • By Date Range
  • Sort Date By
  • Results Per Page
Clear Filters